Abstract: A flow-through monitor for detecting molecular contamination (MC) within a fluid flow. The monitor has a diffusion chamber having an inlet port and an outlet port, and a structure for supporting a fluid flow from the inlet port to the outlet port. The structure includes a flow gap causing a diffusion of molecular contaminants into the diffusion chamber, while substantially preventing, for a rate of the fluid flow above a predetermined magnitude, particulate contaminants within the fluid from entering the diffusion chamber. A SAW device detects molecular contamination interior to the diffusion chamber. Fluid input to the flow-through monitor may be diluted by a pure fluid for extended monitor life. A system for aggregate sampling connects an ensemble manifold upstream of the flow-through monitor. A system for triggered sampling connects a sample preconcentrator downstream of the flow-through monitor. A chemically selective membrane may be located between the flow gap and the SAW.

Abstract: A high throughput microarraying or colony picking robot with an automatic mechanism for exchanging pin heads and an automated washing and drying apparatus. The robot allows a dirty pin head to be deposited on the automated washing and drying apparatus for cleaning without use of the xyz-positioner, while spotting or picking can continue by picking up a clean pin head without having to wait for the dirty pin head to be cleaned. In this way, the speed of operation can be increased without any increase in the acceleration or speed of the x-, y- and z-drives. The dead time normally associated with the washing and drying cycle, which is usually several minutes, is therefore eliminated, and replaced with the much shorter dead time, of only a few tens of seconds, needed for changing between heads.

Abstract: Methods and devices for reducing evaporation of sample materials from the wells of multiwell plates are disclosed which find particular utility when the plates are placed in a stacked configuration. An example of the methods includes providing at least a first multiwell plate which is configured to be placed in a stacked configuration with at least one second multiwell plate, the at least first multiwell plate having a plurality of wells for receiving sample material therein and opposing side walls which extend around the plate and which define a ridge spaced inwardly of the side walls and extending around the plate between the side walls and the plurality of wells, the method including at least partially filling the ridge with a liquid such as water or buffer solution. The ridge can include one or more ribs which extend upwardly from a lower surface of the ridge to help reduce sloshing of the liquid contained within the ridge and to add structural strength and rigidity to the multiwell plate.

Abstract: Titanium dioxide nanopowder is produced by a process, comprising: (a) reacting titanium tetrachloride and an oxygen containing gas in the vapor phase in a flame reactor, at a flame temperature of at least about 800° C. in the presence of (i) water vapor in an amount ranging from about 1000 to about 50,000 parts per million, based on the weight of titanium dioxide under production, (ii) a diluent gas in an amount greater than about 100 mole percent based on the titanium tetrachloride and oxygen containing gas and (iii) a nucleant consisting essentially of a cesium substance wherein the cesium substance is present in an amount ranging from about 10 to about 5000 parts per million, based on the weight of the titanium dioxide under production, the pressure of reaction being sufficient to form titanium dioxide nanopowder.

Abstract: A system for processing residual gas that includes a chamber having at least one baffle for increasing gas flow path, a residual gas inlet mechanism connected to the chamber for supplying residual gas to the chamber, at least one first gas inlet mechanism connected to the chamber for supplying inert gas to the chamber, at least one second gas inlet mechanism connected to the chamber for supplying a reactive gas to the chamber, and a gas outlet mechanism for connected to the chamber for outputting mixed gases from mixing the residual gas, inert gas and reactive gas and non-reacted residual gas, inert gas and reactive gas.

Abstract: A catalyst for the oxidation of volatile organic compounds and carbon monoxide comprising manganese and alumina, such catalyst having been impregnated with a phosphorus compound. The presence of the phosphorus compound results in a significant oxidative conversion of both the volatile organic compounds and the carbon monoxide. The catalyst is especially useful for treating gaseous streams that emanate from industrial sources, such as wood pulp manufacturing plants. The manganese portion of the catalyst is preferably comprised of manganese compounds comprising a defect non-stoichiometric manganese oxide of the type ?-Mn3O4+x, wherein x has the value of 0.1?x?0.25 in respect to about 80 to about 95% of all manganese atoms, and manganese aluminate in respect to the balance of the manganese atoms. The alumina portion of the catalyst is preferably comprised of high temperature forms of alumina of the type comprising ?-Al2O3 and (?+?+?)-Al2O3.

Abstract: Fluorine or a fluorine compound is subjected to a reaction with a spent oxide fuel to produce fluorides of uranium and plutonium, and the fluorides are recovered using a difference in volatility behavior. The spent oxide fuel is subjected to a reaction with an HF gas, whereby uranium, plutonium and most impurities are converted into solid fluorides having low valences or remained as oxides to inhibit volatilization thereof, and then in an F2 fluorination step, the HF fluorination product is subjected to a reaction with a fluorine gas in two stages: one at a low temperature and the other at a high temperature, whereby a certain amount of gaseous uranium and volatile impurities are separated with plutonium kept in a solid form in the first stage, and mixed fluorides of remaining uranium and plutonium are fluorinated into hexafluorides at the same time in the second stage. By such a reprocessing method, plutonium enrichment can be adjusted, uranium and plutonium can be purified, and steps are simplified as well.

Abstract: The invention concerns a process for preparing rare earth borates, and the use of these borates in luminescence. The preparation process is characterized in that it comprises the following steps mixing boric acid and a rare earth salt; a reacting the mixture obtained with a carbonate or a bicarbonate; a calcining the precipitate obtained.

Abstract: Methods are described for the production of hydrogen-bis(chelato)borates of the general formula H[BL1L2] and of alkali metal-bis(chelato)borates of the general formula M[BL1L2] where M=Li, Na, K, Rb, Cs L1=—OC(O)—(CR1R2)n—C(O)O— or —OC(O)—(CR3R4)—O— where n=0 or 1, R1, R2, R3, R4 independently of one another denote H, alkyl, aryl or silyl, L2=—OC(O)—(CR5R6)n—C(O)O— or —OC(O)—(CR7R8)—O— where n=0 or 1, R5, R6, R7, R8 independently of one another denote H, alkyl, aryl or silyl, wherein the respective raw materials are mixed in solid form without the addition of solvents and are reacted. Lithium-bis(oxalato)borate, lithium-bis(malonato)borate, caesium-bis-(oxalato)borate, caesium-bis-(malonato)borate and the mixed salts lithium(lactato,oxalato)borate and lithium(glycolato,oxalato)borate for example may be produced in this way.

Abstract: The invention provides a method of separating a first and a second set of fullerenes in a fullerene mixture. In the method of the invention, a stable fullerene cation is formed of one of the first or the second set of fullerenes. The fullerene cation is then separated from the other set of fullerenes. Optionally, the fullerene cation may be returned to its neutral state. The method of the invention is particularly useful for the purification and separation of endohedral fullerenes from empty fullerenes. However, the method may be applied to the purification of a broad range of endohedral and empty fullerene materials.

Abstract: A high temperature non-aqueous synthetic procedure for the preparation of substantially monodisperse IV-VI semiconductor nanoparticles is provided. The procedure includes introducing a first precursor selected from the group consisting of a molecular precursor of a Group IV element and a molecular precursor of a Group VI element into a reaction vessel that comprises at least an organic solvent to form a mixture. Next, the mixture is heated and thereafter a second precursor of a molecular precursor of a Group IV element or a molecular precursor of a Group VI element that is different from the first is added. The reaction mixture is then mixed to initiate nucleation of IV-VI nanocrystals and the temperature of the reaction mixture is controlled to provide nanoparticles having a diameter of about 20 nm or less.

Abstract: One aspect of the present invention relates to magnetic nanoparticles colloidally stabilized in aqueous milieu by association with an organic phase. The organic phase may be either a fluorinated polymer or an organic hydrocarbon bilayer, wherein the two layers are chemically bonded to each other. The stabilized particles are further non-toxic and provide useful enhancements in bioprocesses. Another aspect of the present invention relates to compositions comprising an oxygen-dissolving fluid vehicle and surface modified, nanometer-sized magnetic particles. The inventive compositions have utility in a wide range of applications, but are particularly suitable for use as recyclable oxygen carriers, separation and purification vehicles, and bioprocessing media, including fermentation processes.

Abstract: Process for preparing mixed oxides by reacting alkoxides of the elements titanium, zirconium, niobium, tantalum or mixtures thereof with metal hydroxides, metal carboxylates, metal hydroxycarbonates, metal carbonates or mixtures thereof of the elements lithium, sodium, potassium, magnesium, calcium, strontium, barium, zinc, cadmium, aluminum, gallium, yttrium, lanthanum, praseodymium, neodymium, samarium, dysprosium, europium, lead, bismuth or mixtures thereof in a C1–C8-alkanol, in a glycol ether or in a mixture thereof at from 50 to 200° C.

Abstract: The present invention provides steam reforming catalyst compositions containing Pd and Zn, and methods of steam reforming alcohols over a catalyst. Surprisingly superior results and properties of the present invention, including low temperature activity and/or low carbon monoxide output, are also described. Methods of making a steam reforming catalyst are also provided.

Abstract: Zeolites having the IFR structure and containing aluminum in their crystal structure can be made by preparing a reaction mixture comprising a zeolite which is an active source of aluminum oxide, an active source of alkali metal oxide, an active source of an oxide of a tetravalent element, an organic template selected from the group consisting of a 1-benzyl-4-aza-1-azonia-bicyclo[2.2.2]octane cation and a N-benzyl quinuclidinium cation, and maintaining the reaction mixture under conditions sufficient to form crystals of the zeolite.

Abstract: Imaging agents for magnetic resonance imaging are disclosed. Methods of monitoring angiogenesis and the growth and remission of tumor tissue are also disclosed. Methods of monitoring blood clot formation and dissolution are additionally disclosed. Methods of monitoring wound healing are further disclosed. A kit for obtaining an image of a biological structure is further disclosed.

Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21–29, 39, 42, 44 or 57–83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

Abstract: The metal complexes of general formula I in which Hal stands for bromine or iodine and A1 and A2 have different meanings, are suitable as contrast media.

Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam, or a pharmaceutically acceptable salt thereof, delivered as an aerosol or dry powder formulation.

Abstract: Novel indanylidene compounds can be used as UV-A filters in cosmetic compositions for protecting skin and hair and for technical applications.

Abstract: What is described herein is an antiperspirant composition including an active antiperspirant ingredient, and a phenylethyl, benzyl or substituted benzyl ester as additive therein, which is an aryl carboxylic ester of 2-phenylethyl alcohol, 1-phenylethyl alcohol or benzyl alcohol, which leaves a reduced visible white chalky residue on the skin of the user.

Abstract: IR 6 (Cosmetics, Toiletry and Fragrance Association, Inc., 7th ed. 1997). Viscosities are measured using Brookfield viscometers (1,000–20,000 cps, Spindle No. 5, 20 rpm, 60 second run, 25 degrees C.) unless otherwise indicated. 967-00—IR # 6961-00-1-A low viscosity, stable dispersion of behenyl alcohol comprising: (a) 10–40 weight % on an actives basis of behenyl alcohol; (b) 1.0–8.0 weight % of an anionic surfactant selected from the group consisting of sodium lauryl ether sulfate, sodium lauryl sulfate, magnesium lauryl ether sulfate, magnesium lauryl sulfate, calcium lauryl ether sulfate, calcium lauryl sulfate, ammonium lauryl ether sulfate, and ammonium lauryl sulfate; and (c) 1.0–3.0 weight % (on an actives basis) of a betaine selected from the group consisting of C12–18 amidopropylbetaine; wherein the dispersion has a stability of at least 3 months at a temperature of 49 degrees C., a viscosity in the range of 1,000–20,000 centipoise, and no more than 0.2 weight % of cationic material.

Abstract: Polymeric reagents comprising a polymer attached, either directly or through one or more atoms to a ketone or a related functional group such as ketone hydrate, thione, monothiohydrate, dithiohydrate, hemiketal, monothiohemiketal, dithiohemiketal, ketal, or dithioketal are provided. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.

Abstract: The present invention provides multivalent vaccines for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom vaccines.

Abstract: The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human granulocyte macrophage colony stimulating factor (GM-CSF) to result in GM-CSF proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

Abstract: The invention concerns a derivative of viral regulatory protein or a fragment of viral regulatory protein or of the alpha interferon or a fragment of alpha interferon, which is carboxymethylated, a method for preparing, use of the resulting product in a method of treatment for the human or animal body, a pharmaceutical composition and a vaccine containing as active principle, at least one of the carboxymethylated proteins or fragments.

Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.

Abstract: A substantially non-toxic fraction isolated from snake venom is disclosed, which fraction has an analgesic effect. The fraction has the characteristics of a fraction from snake venom purified on a Mono Q ion exchange column. Also described are a pharmaceutical composition for use as an analgesic comprising the non-toxic fraction, and a method for the relief of pain comprising administrating the non-toxic fraction.

Abstract: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.

Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine receptor Bonzo (also referred to as STRL33, TYMSTR, HBMBU14 and CXCR6) and blocks the binding of a ligand (e.g., SExCkine (also referred to as chemokine alpha-5 and CXCL16) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to Bonzo and inhibit the binding of a ligand (e.g., SExCkine) and/or modulate a function of Bonzo. The invention relates to an antibody or antigen-binding fragment thereof which binds to the CXC chemokine SExCkine (also referred to as chemokine alpha-5) and inhibit binding of SExCkine to receptor (e.g., Bonzo). The invention also relates to targeting molecules which contain a first binding moiety which binds to mammalian Bonzo and a second binding moiety which binds to a molecule expressed on the surface of a target cell.

Abstract: A method for the improvement of neuronal regeneration by prevention or inhibition of basal membrane formation induced by a lesion of neuronal tissue.

Abstract: The present invention relates to methods and compositions for counteracting and reversing disease-causing signaling defects in disorders with underlying signal transduction aberrations, including but not limited to rheumatoid arthritis.

Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.

Abstract: Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.

Abstract: The present invention is based on the discovery of a composition that provides targeted ubiquitination. Specifically the composition contains a ubiquitin pathway protein binding moiety which recognizes a ubiquitin pathway protein and a targeting moiety which recognizes a target protein. In addition, the present invention provides libraries of compositions, where each composition contains a ubiquitin pathway protein binding moiety and a member of a molecular library. The libraries of the present invention can be used to identify proteins involved in a predetermined function of cells.

Abstract: The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with uterine cancer. The biological compositions can be used to retard the growth of uterine cancer cells and/or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.

Abstract: Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to treat gastroparesis in a subject (e.g., stimulating stomach contraction, reducing abnormal gastric acid and/or pepsin production), as a result of having been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength. Also included are methods of making and using such compositions.

Abstract: The process of treating sea algae/halophytes. The sea algae/halophyte in an aqueous solution containing an acid is soaked for a sufficient length of time to substantially reduce the mineral content of the sea algae/halophyte. The initial mineral content is expressed on the basis of the total ash content of the untreated sea algae/halophyte in the dried state. The soak-treated sea algae is separated from the aqueous solution. The separated sea algae/halophyte can be dried to provide a dried sea algae/halophyte product having substantially reduced mineral content and increased nutritional value.

Abstract: Isolated polynucleotide molecules provide recombinant PIV genomes and antigenomes for production of recombinant PIV vaccines. The recombinant genome or antigenome can be expressed with a nucleoprotein (N), phosphoprotein (P), and a large (L) polymerase protein to produce isolated infectious PIV particles. The recombinant PIV genome and antigenome can be modified to produce desired changes, for example to incorporate attenuating mutations from biologically derived PIV mutants or to create chimeric PIV clones, to generate attenuated, immunogenic viruses for vaccine use.

Abstract: Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibodies, and an additional anti-inflammatory agent, especially corticosteroids, as well as anti-inflammatory antibodies, especially anti-interleukin-6. Also disclosed are methods of using such compositions to treat and/or prevent respiratory diseases. Such compositions may optionally contain other non-antibody anti-viral agents.

Abstract: It was found that a mutation of an amino acid at a specific position in the P protein of a morbillivirus gives a temperature-sensitivity character to a virus. By introducing this mutation, a virus to which a temperature-sensitivity character has been introduced can be produced. According to this invention, attenuated viruses useful in the preparation of vaccines can be easily produced.

Abstract: The present invention is directed to processes and compositions for protecting host animals (e.g., chickens) from exposure to virulent infectious bronchitis virus. In ovo administration of live, avirulent strains of IB at appropriate dosage levels on a per egg basis provides an effective and efficient vaccination having acceptable safety and efficacy features.

Abstract: Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and compositions for detecting HCMV infections and in immunogenic compositions for Preventing HCMV infections.

Abstract: Use of botulin toxin to obtain a product intended to be administered intramuscular with lissive effect in treating articular pathologies, particularly coxarthrosis, or arthrosis of the hip, epicondylitis of the elbow and rotator muscle cap pathology of the shoulder.

Abstract: A method and pharmaceutical combination for treating hepatitis C by administering to a hepatitis C patient an effective amount of at least one alpha thymosin peptide, in combination with administration to the hepatitis C patient of an effective amount of at least one interferon, and optionally in combination with administration of at least one antiviral agent such as ribavirin.

Abstract: There is provided a method of forming a segmented composition utilizing the thermal exchange properties of a first component that solidifies when cooled, and a second component that solidifies when heated. When an amount of the heat from the first component is transferred to the coolness of the second component, and vice versa, both the first and second components are provided with structural integrity, thus forming the segmented composition. There is also provided a method and an apparatus that can form a segmented cosmetic composition. The segmented cosmetic composition has at least two components. A first component is preferably a molten wax. A second component is preferably a smectite clay dispersion. One of the components fully surrounds, partially surrounds, or is adjacent to the other component.

Abstract: The invention relates to novel biphenylcarboxamides of the formula (I) in which R1, R2, m, n, R3, Y and A are as defined in the disclosure, to a plurality of processes for preparing these substances and their use for controlling unwanted microorganisms, and to novel intermediates and their preparation.

Abstract: A non-toxic, germicide, fungicide and healing composition and a method of topically applying the composition in powdered form to the skin of domesticated farm animals including dairy cattle are disclosed. The composition comprises (a) finely divided, particulate chlorhexidine-containing material, (b) finely divided, particulate zinc-containing material and (c) an inert powdered carrier, with the chlorhexidine-containing material and the zinc-containing material being present in an amount to achieve effective germicidal activity. The chlorhexidine-containing material is preferably chlorhexidine acetate. The zinc-containing material is preferably selected from the group consisting of zinc stearate, zinc chloride, zinc nitrate, zinc oleate, zinc oxide, zinc phosphate, zinc peroxide, zinc iodide, elemental zinc and mixtures thereof.

Abstract: The invention is related to biomimetic gels that are prepared enzymatically, using a transglutaminase to cross-link polymer-peptide conjugates of rational design.

Abstract: A metallic composite coating, and methods for forming same, for an implantable medical device is disclosed. The composite coating comprises at least one metal or metallic tie layer formed on the surface of the device, followed by an electroless electrochemical cladding of one or more additional layers over the tie layer. One or more therapeutic or biologically active agents are co-deposited with at least one of the electroless electrochemical claddings.